ArticleInfection & chemotherapy2014
Early Additional Immune-Modulators for Mycoplasma pneumoniae Pneumonia in Children: An Observation Study.
Article in Infection & chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Effect of montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia.The Journal of international medical research · 2019Trial
- Clinical differentiation between pediatric pulmonary tuberculosis andExperimental and therapeutic medicine · 2026Review
- Impact of early corticosteroid therapy on short-term pulmonary function and clinical outcomes in children with severeFrontiers in pediatrics · 2026Article
- Combining circ_0054633 and clinical features to predict refractory Mycoplasma pneumoniae pneumonia in children.Scientific reports · 2025Article
- Case Report: PositiveFrontiers in pediatrics · 2025Article
- The molecular characteristics, diagnosis, and treatment of macrolide-resistantFrontiers in pediatrics · 2023Review
- RefractoryJournal of clinical medicine · 2022Review
- Potential therapeutic approach of intravenous immunoglobulin against COVID-19.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021Review
- Consideration in treatment decisions for refractory Mycoplasma pneumoniae pneumonia.Clinical and experimental pediatrics · 2021Article
- β-Caryophyllene ameliorates the Mycoplasmal pneumonia through the inhibition of NF-κB signal transduction in mice.Saudi journal of biological sciences · 2021Article
- Macrolide-Resistant and Macrolide-SensitiveJournal of clinical medicine · 2021Article
- Early Confirmation ofDiagnostics (Basel, Switzerland) · 2021Article
- Case Report: Clinical Analysis of FulminantFrontiers in pediatrics · 2021Article
- Molecular Detection and Evaluation of MLـ ResistanceReports of biochemistry & molecular biology · 2020Article
- Immunopathogenesis of COVID-19 and early immunomodulators.Clinical and experimental pediatrics · 2020Article
- The Prevalence ofReports of biochemistry & molecular biology · 2020Article
- Clinical Role of Serum Interleukin-17A in the Prediction of RefractoryInfection and drug resistance · 2020Article
- Evaluation of Risk Factors for Exacerbations in Children with Adenoviral Pneumonia.BioMed research international · 2020Article
- Early Corticosteroid Therapy forJournal of clinical medicine · 2019Article
- Dietary Supplementation with Low-Molecular-Weight Fucoidan Enhances Innate and Adaptive Immune Responses and Protects againstMarine drugs · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycoplasma pneumoniae (MP) pneumonia is a self-limiting disease, but some patients complain of progressive pneumonia, despite of appropriate antibiotic treatment. We aimed to introduce the role of immune-modulators (corticosteroid and/or intravenous immunoglobulin, IVIG) treatment for childhood MP pneumonia based on previous our experiences. MATERIALS AND
methodsA retrospective case series analysis for 183 children with MP pneumonia was performed. MP pneumonia patients were diagnosed by two Immunoglobulin M (IgM) tests: the micro-particle agglutination method (≥1:40) and the cold agglutination test (≥1:4), and were examined twice at the initial admission and at discharge. Among 183 MP pneumonia patients, 90 patients with persistent fever for over 48 hours after admission or those with severe respiratory symptoms and signs received additional prednisolone (82 patients, 1 mg/kg/day) or intravenous methylprednisolone (8 patients, 5-10 mg/kg/day) with antibiotics. Four patients with aggravated clinical symptoms and chest radiographic findings after corticosteroid treatment received IVIG (1 g/kg/day, 1-2 doses).
resultsMean age of 183 patients was 5.5 ± 3.2 years (6 months-15 years), and the male: female ratio was 1.1:1 (96:87). Fifty-seven patients (31%) were seroconverters and 126 seropositive patients showed increased diagnostic IgM antibody titres during admission (over 4 folds). The majority of the patients who received corticosteroids (86/90 cases) showed rapid defervescence within 48 hours with improved clinical symptoms, regardless of the used antibiotics. Also, 4 patients who received additional IVIG improved both clinically and radiographically within 2 days without adverse reaction.
conclusionsIn the era of macrolide-resistant MP strains, early additional immune-modulator therapy with antibiotics might prevent from the disease progression and reduce the disease morbidity without adverse reaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.